Deciding Whether to Recommend a New Vaccine in a Low-Resource Setting
A national immunization advisory group must decide whether to add a new vaccine to the routine schedule for infants. A randomized trial in a similar country showed 70% efficacy against severe disease over 12 months, with a number needed to vaccinate of about 400 to prevent one severe case. The vaccine costs $18 per dose, requires three doses plus a cold chain (2–8°C), and has a 5% rate of moderate local reactions. The country's cold-chain capacity is stretched: 30% of health facilities report refrigerator outages in the past year. Severe disease incidence is estimated at 1.2 per 1,000 infants per year, and case fatality is about 4% with current care. The health ministry has asked for a recommendation in 4 weeks, and a manufacturer offers a discounted price if the country commits to a national rollout.
1. Using the trial data, estimate the expected health impact of a national rollout to 100,000 infants and identify the key assumptions.
Read the worked answer
Assume full three-dose coverage and that trial efficacy (70%) applies to the local setting:
- Severe cases without vaccine: 100,000 × 1.2/1,000 = 120 severe cases/year.
- Cases prevented: 120 × 0.70 = 84 severe cases/year (consistent with NNV ≈ 400: 100,000/400 = 250 prevented? - note the discrepancy; NNV of 400 implies ~250 prevented, so verify whether NNV was computed over a different time horizon or population).
- Deaths averted: 84 × 0.04 ≈ 3.4 deaths/year (assuming vaccine prevents the same fraction of fatal cases and case fatality is unchanged).
Key assumptions: full coverage (unrealistic at 30% cold-chain outage), efficacy generalizes to local strains and schedule, NNV and efficacy are consistent (they are not - reconcile before publishing), no indirect/herd effects, and case fatality applies to prevented cases. The honest message: benefits are real but modest in absolute terms, and coverage will be the binding constraint.
2. How should the cold-chain constraint and cost shape the recommendation? What implementation conditions would you attach?
Read the worked answer
Cold-chain is a feasibility and equity issue, not a footnote. With 30% of facilities reporting outages, a 2–8°C three-dose vaccine risks potency loss and wasted doses, which erodes the already modest benefit and wastes $54 per fully vaccinated child.
Conditions to attach:
- Phased introduction in facilities with reliable cold chain, expanding as capacity improves - rather than a simultaneous national rollout.
- Cold-chain investment (refrigerators, temperature monitoring, backup power, stock management) funded as part of the decision, with a readiness assessment before each phase.
- Cost-effectiveness and budget analysis: $18 × 3 = $54 per child; at 100,000 infants that is $5.4M, plus cold-chain and delivery costs. Compare cost per severe case and per death averted against other priorities.
- Do not let the discount drive the decision: a commitment-for-discount arrangement should not override readiness; negotiate for tiered or volume-based pricing contingent on phased uptake.
- Monitoring: track coverage, cold-chain failures, adverse events, and disease incidence.
Recommendation: conditional 'yes' with phased introduction and funded cold-chain upgrades, not an unconditional national rollout.
3. A ministry official argues that 3.4 deaths averted per 100,000 infants is 'too small to justify the cost.' How would you respond, and what additional considerations belong in the decision?
Read the worked answer
Respond by reframing the metric and being transparent about uncertainty:
- Absolute vs relative: 3.4 deaths per 100,000 infants is small per cohort but represents real families, and cumulative over years and across the birth cohort (e.g., 1 million births over a decade) it is substantial.
- Beyond mortality: the vaccine prevents severe illness, hospitalizations, and long-term sequelae; these carry costs and suffering not captured by deaths alone. Cost per severe case averted and per quality-adjusted life year should be compared with the country's cost-effectiveness threshold.
- Uncertainty: the estimate rests on trial efficacy, local incidence, and coverage assumptions; sensitivity analysis should show a range, not a point.
- Equity: severe disease burden likely falls disproportionately on poorer, remote families with worse access to care - the vaccine may narrow inequity even if aggregate numbers are modest.
- Opportunity cost: compare against other uses of the same budget; the right question is not 'is 3.4 deaths worth it?' but 'is this the best use of marginal health dollars?'
A defensible decision process combines cost-effectiveness, budget impact, equity, feasibility, and political commitment - and documents the reasoning so the choice is transparent and revisitable.